3 Einträge gefunden

1. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

   1. Weisel, Katja
   2. Majer, Istvan
   3. DeCosta, Lucy
   4. Oriol, Albert
   5. Goldschmidt, Hartmut
   6. Ludwig, Heinz
   7. Campioni, Marco

   2020 - Forschungsinformationssystem des UKE
2. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

   1. Ludwig, Heinz
   2. Pönisch, Wolfram
   3. Knop, Stefan
   4. Egle, Alexander
   5. Hinke, Axel
   6. Schreder, Martin
   7. Lechner, Daniel

   2020 - Forschungsinformationssystem des UKE
3. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

   1. Weisel, Katja
   2. Ludwig, Heinz
   3. Rieth, Achim
   4. Lebioda, Andrea
   5. Goldschmidt, Hartmut

   2020 - Forschungsinformationssystem des UKE